A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, retrospective cohort analysis comparing 321 CL...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Mato, Anthony R., Roeker, Lindsey E., Eyre, Toby A., Nabhan, Chadi, Lamanna, Nicole, Hill, Brian T., Brander, Danielle M., Barr, Paul M., Lansigan, Frederick, Cheson, Bruce D., Singavi, Arun K., Yazdy, Maryam Sarraf, Shah, Nirav N., Allan, John N., Bhavsar, Erica B., Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen J., Williams, AnnaLynn M., Skarbnik, Alan P., Goy, Andre H., Goodfriend, Julie M., Dorsey, Colleen, Coombs, Catherine C., Tuncer, Hande, Ujjani, Chaitra S., Jacobs, Ryan, Winter, Allison M., Pagel, John M., Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Zelenetz, Andrew, Kirkwood, Amy A., Fox, Christopher P.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2019
Предметы:
Lymphoid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538868/
https://ncbi.nlm.nih.gov/pubmed/31101647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000180
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы